<p>Severe eosinophilic asthma can now be treated with biologic therapies that reduce attacks and, in some cases, allow corticosteroid dose reductions. However, not all patients respond to these treatments, and it remains difficult to predict in advance who will benefit from them. A study conducted by s</p>